Advanced Oxidation Protein Products as a Novel Marker of Oxidative Stress in Postmenopausal Osteoporosis.
BACKGROUND
Advanced oxidation protein products (AOPPs) are acknowledged as a novel marker of oxidation-mediated protein damage. This study aimed to investigate the plasma levels of AOPPs in postmenopausal osteoporotic women, and to determine the relationship between AOPPs accumulation and lumbar bone mineral destiny (BMD) or bone turnover markers.


METHODS
Lumbar BMD was measured by dual-energy X-ray absorptiometry. Plasma AOPPs levels as a marker of protein oxidation damage and malondialdehyde (MDA) levels as a marker of lipid peroxidation were measured by spectrophotometry. The concentrations of 2 specific markers of bone turnover, bone-specific alkaline phosphatase (BALP) and tartrate-resistant acid phosphatase5b, (TRACP 5b) were quantified using ELISA kits.


RESULTS
We recruited 60 postmenopausal women meeting osteoporosis (OP) diagnostic criteria of World Health Organization (WHO) and 60 postmenopausal women without OP. Plasma levels of AOPPs (P<0.001), BALP (P<0.001) and TRACP 5b (P<0.001) were statistically significantly increased in the postmenopausal osteoporotic women compared with controls, but there was no statistically significant difference in MDA (P=0.124) between the 2 groups. Plasma AOPPs levels were negatively correlated with lumbar BMD and positively correlated with bone turnover markers both in postmenopausal osteoporotic women and in all subjects. However, plasma MDA levels were not correlated with lumbar BMD or bone turnover markers.


CONCLUSIONS
In postmenopausal osteoporotic women elevated AOPPs is associated with reduced BMD and increased bone turnover markers. Because AOPPs is stable and easy to detect it may be used as a simple plasma marker to predict the severity of postmenopausal OP.
Department of Spinal Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (mainland).
Qian
Q
Wu
Department of Spinal Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (mainland).
Zhao-Ming
ZM
Zhong
Department of Oncology, Affiliated Jiujiang Hospital of Nanchang University, Jiujiang, Jiangxi, China (mainland).
Ying
Y
Pan
Department of Orthopedics, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China (mainland).
Ji-Huan
JH
Zeng
Department of Spinal Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (mainland).
Shuai
S
Zheng
Department of Spinal Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (mainland).
Si-Yuan
SY
Zhu
Department of Spinal Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (mainland).
Jian-Ting
JT
Chen
D000135:Acid Phosphatase / Q000097:blood; D062107:Advanced Oxidation Protein Products / Q000097:blood*; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D016723:Bone Remodeling; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000097:blood; D008159:Lumbar Vertebrae; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood* / Q000503:physiopathology; D018384:Oxidative Stress; D000071681:Tartrate-Resistant Acid Phosphatase
D062107:Advanced Oxidation Protein Products; D015415:Biomarkers; D007527:Isoenzymes; D000469:Alkaline Phosphatase; C000605510:ACP5 protein, human; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase